Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
India Globalization Capital Inc
IGC | US
0.40
USD0.01
2.41%
IGC | US
About India Globalization Capital Inc
Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
Earnings date
30/06/2024
As of date
21/10/2024
Close
0.40
Open
0.40
High
0.41
Low
0.39
IGC Pharma Inc. a clinical stage biotechnology company engages in developing cannabinoid-based formulations for treating diseases and conditions including Alzheimer's disease dysmenorrhea premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1 which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development. It also markets Holief a wellness brand that targets women experiencing premenstrual syndrome and menstrual cramps. The company was formerly known as India Globalization Capital Inc. and changed its name to IGC Pharma Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac Maryland.
View LessIGC | US
Risk
92.0
Sharpe
0.24
Luna's Score
42/100
Recommendation
Sell
Luna says (IGC | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
49.5%1 month
92.0%3 months
65.2%6 months
87.0%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
3.85
Debt to equity
0.04
Debt to assets
0.03
Ent. to EBITDA
-2.54
Ent. to rev.
27.13
PEG
-
Other Fundamentals
EBITDA
-9.40M
MarketCap
30.25M
MarketCap(USD)
30.25M
Div. yield
-
Op. margin
-871.32
Erngs. growth
-
Rev. growth
-51.00
Ret. on equity
-126.20
Short ratio
2.70
Short perc.
3.24
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.06
Range1M
0.14
Range3M
0.16
Volumes: Market Activity
Rel. volume
0.49
Price X volume
136.15K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -2.54 | 24.85 | Cheaper |
| Ent. to Revenue | 27.13 | 361.91 | Cheaper |
| PE Ratio | - | 30.05 | - |
| Price to Book | 3.85 | 13.15 | Cheaper |
| Dividend Yield | - | 2.94 | - |
| Std. Deviation (3M) | 65.17 | 65.24 | Par |
| Debt to Equity | 0.04 | -1.88 | Expensive |
| Debt to Assets | 0.03 | 0.48 | Cheaper |
| Market Cap | 30.25M | 3.71B | Emerging |
